Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer

類似資料

• Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
  著者:: Chen, Xiaoying, 等
  出版事項: (2019)
• Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))
  著者:: Hurst, Susan, 等
  出版事項: (2014)
• PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
  著者:: Pegram, Mark D., 等
  出版事項: (2018)
• Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
  著者:: Lammers, Philip E., 等
  出版事項: (2018)
• A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)(1)
  著者:: Yin, Donghua, 等
  出版事項: (2014)